Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01449370 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 125
- Enrollment target
NCT01449370 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 125 participants.
The verdict
NCT01449370, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 125 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) and/or optimal biologic dose(OBD), safety and tolerability, dose-limiting toxicity (DLT) of TAK-117 when administered orally in subjects with advanced solid malignancies.
Interventions
- DRUG TAK-117
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2011-10 |
| Est. Completion | 2016-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01449370
The ClinicalTrials.gov registry entry for NCT01449370 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAK-117 is the first listed.
NCT01449370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01449370 about?
NCT01449370 is a clinical study titled "Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer". The purpose of this study is to determine the maximum tolerated dose (MTD) and/or optimal biologic dose(OBD), safety and tolerability, dose-limiting toxicity (DLT) of TAK-117 when administered orally in subjects with advanced solid malignancies.
What is the current status of trial NCT01449370?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 125 participants. The study started on 2011-10. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01449370?
The interventions under investigation include: TAK-117 (DRUG).
Who is sponsoring clinical trial NCT01449370?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.